Prosecution Insights
Last updated: November 04, 2026
Application No. 18/557,102

GM3 SYNTHASE VECTORS AND USES THEREOF

Non-Final OA §103§DP
Filed
Oct 25, 2023
Priority
Apr 26, 2021 — provisional 63/179,684 +1 more
Examiner
GU, QINHUA
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Clinic for Special Children, Inc.
OA Round
2 (Non-Final)
77%
Grant Probability
Favorable
2-3
OA Rounds
9m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
66 granted / 86 resolved
+16.7% vs TC avg
Strong +27% interview lift
Without
With
+26.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
44 currently pending
Career history
136
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
46.0%
+6.0% vs TC avg
§102
16.3%
-23.7% vs TC avg
§112
27.5%
-12.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 86 resolved cases

Office Action

§103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Applicant’s submission filed 07/27/2026 has been received and entered. Claims 1, 3, 5, 7, 9, 11, 13, 15 and 18-19 have been cancelled. Claims 55, 58-60 and 74-75 have been amended. Accordingly, claims 54-55, 58-60, 68-69 and 73-75 are pending and under current examination. Status of Prior Rejections/Response to Argument The objection to claims 55, 58-60 and 74-75 is withdrawn: Applicant’s amendment to claim 55, 58-60 and 74-75 is effective to obviate the objection on record. The objection is withdrawn. The rejection to claims 58 and 75 under 35 USC 112(b) is withdrawn: Applicant’s amendment to claim 58 and 75 obviates the rejection on record. The rejection is withdrawn. This is a second non-final rejection. The Examiner has re-evaluated the priority date of instant application. Priority The instant application is a national stage entry of PCT application PCT/US2022/025208, filed 10/25/2023 under 35 USC 371. Acknowledgement is made of the applicant’s claim for benefit to prior-filed U.S. provisional patent application 63/179,684, which was filed 04/26/2021. However, the limitation of “an AAV Cap-Mac capsid protein” in the independent claim 54 is only disclosed in the PCT application PCT/US2022/025208, which was filed 04/18/2022. Therefore claim 54 and the dependent claims 55, 58-60, 68-69 and 73-75 have a priority date of 04/18/2022 but fail the benefit of priority from the ‘684 Provisional application dated 04/26/2021. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 54-55, 58-60, 68-69 and 73-75 are rejected under 35 U.S.C. 103 as being unpatentable over Gao et al. (WO 2020/210570 A2, cited in IDS) in view of Chuapoco et al. (BioRxiv, online on January 09, 2022, cited in IDS). Gao et al. teach compositions and methods for expressing one or more Ganglioside GM3 synthase (GM3S) isoforms in a cell or subject (Abstract). Regarding claim 54, Gao et al. teach a recombinant adeno-associated virus (rAAV) comprising: (i) a capsid protein; and (ii) an isolated nucleic acid (p4, L12-13). An isolated nucleic acid comprising: (i) a first region comprising a first adeno-associated virus (AAV) inverted terminal repeat (ITR); and (ii) a second region comprising a transgene having a nucleic acid sequence encoding one or more monosialodihexosylganglioside synthase (GM3S) protein isoforms. GM3S isoforms including one or more 1a Type 1 isoforms, 1a Type 2 isoforms, 1b Type 1 isoforms, 1b Type 2 isoforms, 1c isoforms, and combinations thereof (see p1, L21-22). In some embodiments, a transgene is flanked by AAV ITRs (p3, L26-27). Gao et al. do not teach the rAAV comprises an AAV Cap-Mac capsid protein. However, this was disclosed by Chuapoco et al. at the time of instant invention. Chuapoco et al. teach AAV.CAP-Mac, an engineered AAV variant that enables systemic, brain-wide gene delivery in infants of two Old World primate species—the rhesus macaque (Macaca mulatta) and the green monkey (Chlorocebus sabaeus) (Abstract). Regarding claim 54, Chuapoco et al. teach AAV.CAP-Mac, an engineered AAV9 variant that efficiently transduces multiple neuronal subtypes throughout cortical and subcortical brain regions of infant Old World primates after IV administration (p4, L86-88). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Gao et al.’s rAAV comprising GM3S Ia Type 2 protein isoforms, and use AAV.CAP-Mac capsid protein as taught by Chuapoco et al.. The skilled artisan would have been motivated to use AAV.CAP-Mac capsid protein since Gao et al. teach GM3 synthase (GM3S) deficiency is a rare monogenic neurological disorder (p1, L9), which requires the therapeutic rAAV efficiently deliver to the brain (see p4, L17), and Chuapoco et al. teach AAV.CAP-Mac capsid can efficiently transduces multiple neuronal subtypes throughout cortical and subcortical brain regions, which is beneficial for the gene therapy. There would be a reasonable expectation of success of having AAV.CAP-Mac capsid protein since Chuapoco et al. teach the CAP-Mac selection and mutation sites comparing to AAV9 (see figure 1). Regarding claims 55, Gao et al. teach in some embodiments, an isolated nucleic acid includes an RNA transcript having one or more initiation codons (referred to as M1, M2, M3, etc.) which encodes one or more variants of a GM3S isoform (e.g., one or more variants of a Ia Type 1 isoform, one or more variants of a Ia Type 2 isoform, one or more variants of a lb Type I isoform, one or more variants of a lb Type 2 isoform, etc.). An initiation codon may be a codon encoding a methionine (M, encoded by AUG codon) or a codon encoding an amino acid that is not methionine but is capable of initiation of protein translation (e.g., leucine, encoded by CUG codon) (p8, L10-16). Regarding claim 58, following the discussion above, Gao et al. teach in some embodiments, a transgene further comprises a Kozak sequence (GCCACC) operably linked to the nucleic acid sequence encoding the one or more GM3S protein isoforms (p3, L16-17). Regarding claim 59, Gao et al. teach each of the one or more GM3S protein isoforms comprises or consists of the amino acid sequence set forth in any one of SEQ ID NOs: 8-10 (p3, L19-20). Herein the SEQ ID NO: 8 is 100% identical to SEQ ID NO: 8 as recited in instant claim (sequence alignment is provided). Regarding claim 60, following the discussion above, Gao et al. teach in some embodiments, a transgene further comprises a promoter operably linked to the nucleic acid sequence encoding the one or more GM3 synthase protein isoforms. In some embodiments, a promoter is a chicken beta-actin (CBA) promoter (p3, L21-23). Regarding claim 68, the disclosure provides an isolated nucleic acid comprising the sequence set forth in any one of SEQ ID NOs: 1-7 (p3, L31-32), herein the of SEQ ID NO:1 is 100% identical to SEQ ID NO: 1 as recited in instant claim (sequence alignment is provided). Regarding claim 69, following the discussion above, Gao et al. teach in some embodiments, an isolated nucleic acid described by the disclosure comprises one or more miRNA binding sites (p4, L1-2). Regarding claim 73, following the discussion above, Gao et al. teach in some embodiments, an rAAV vector or rAAV particle comprises a mutant ITR that lacks a functional terminal resolution site (TRS, p15, L23-24). A rAAV vector comprising an ITR lacking a functional TRS produces a self-complementary rAAV vector (p15, L29-30). Regarding claim 74, following the discussion above, Gao et al. teach in some embodiments, an isolated nucleic acid includes an RNA transcript having one or more initiation codons (referred to as M1, M2, M3, etc.) which encodes one or more variants of a GM3S isoform (e.g., one or more variants of a Ia Type 1 isoform, one or more variants of a Ia Type 2 isoform, one or more variants of a lb Type I isoform, one or more variants of a lb Type 2 isoform, etc.). This teaching reads on the rAAV encodes one or more GM3S Ia Type 2 protein isoforms can be translated from an M3 initiation codon. Regarding claim 75, following the discussion above, Gao et al. teach in some embodiments, a transgene further comprises a Kozak sequence (GCCACC) operably linked to the nucleic acid sequence encoding the one or more GM3S protein isoforms (p3, L16-17). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 54-55, 60, 68-69 and 74 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 and 6-8 of U.S. Patent No. US 12553036 B2. in view of Chuapoco et al. (BioRxiv, online on January 09, 2022, cited in IDS). Although the claims at issue are not identical, they are not patentably distinct from each other because the patent renders obvious to the instant claims. Regarding claims 54-55, 68 and 74, it is noted that claims 55 and 74 are product-by-process claims, which are directed to GM3S Ia Type 2 protein isoforms. Patent claim 1 teaches an isolated nucleic acid comprising a first region comprising a first adeno-associated virus (AAV) inverted terminal repeat (ITR); and a second region comprising a transgene comprising a nucleic acid sequence that consists of the nucleotide sequence set forth in SEQ ID NO: 43 and encodes a GM3S Ia Type 2 protein isoform. The SEQ ID NO: 43 in patent claim 1 is 100% identical to SEQ ID NO: 43 in instant claim 68. Patent claim 4 teaches the isolated nucleic acid further comprising a third region comprising a second ITR wherein the first region and the third region flank the transgene. Patent claim 8 teaches a vector comprising the isolated nucleic acid. The patent claims do not teach the isolated nucleic acid is in an rAAV which having AAV Cap-Mac capsid protein. However, this was disclosed by Chuapoco et al.. Chuapoco et al. teach AAV.CAP-Mac, an engineered AAV9 variant that efficiently transduces multiple neuronal subtypes throughout cortical and subcortical brain regions of infant Old World primates after IV administration (p4, L86-88). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the isolated nucleic acid comprising GM3S Ia Type 2 protein isoforms of the patent, and have this isolated nucleic acid in an rAAV comprising AAV.CAP-Mac capsid protein as taught by Chuapoco et al.. The skilled artisan would have been motivated to use AAV.CAP-Mac capsid protein to efficiently transduce the rAAVs to multiple neuronal subtypes throughout cortical and subcortical brain regions. There would be a reasonable expectation of success of having AAV.CAP-Mac capsid protein since Chuapoco et al. teach the CAP-Mac selection and mutation site comparing to AAV9 (see figure 1). Regarding claim 60, patent claims 2-3 teach the transgene comprising promoter operably linked to the nucleic acid sequence encoding the GM3 synthase Ia Type 2 protein isoform, wherein the promoter is a chicken beta-actin (CBA) promoter. Regarding claim 69, patent claim 6-7 teach the isolated nucleic acid comprises a fourth region comprising one or more miRNA binding sites, render obvious to instant claim. Claims 54-55, 60, 68-69 and 74 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 42-43, 57-59 and 61-62 of copending Application No. 19/446,200 (reference application) in view of Chuapoco et al. (BioRxiv, online on January 09, 2022, cited in IDS). Although the claims at issue are not identical, they are not patentably distinct from each other because the reference claims render obvious to the instant claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Regarding claims 54-55, 68 and 74, it is noted that claims 55 and 74 are product-by-process claims, which are directed to GM3S Ia Type 2 protein isoforms. Co-pending claims 42-43 and 57-59 teach a recombinant adeno-associated virus (rAAV) comprising a capsid protein and an isolated nucleic acid comprising: (a) a first region comprising a first adeno-associated virus (AAV) inverted terminal repeat (ITR); and (b) a second region comprising a transgene comprising a nucleic acid sequence that consists of the nucleotide sequence set forth in SEQ ID NO: 43 and encodes a GM3S Ia Type 2 protein isoform, wherein the capsid can be AAV9 capsid protein or a variant thereof, and the transgene further comprises a promoter operably linked to the nucleic acid sequence encoding the GM3 synthase Ia Type 2 protein isoform. The promoter is a chicken beta-actin (CBA) promoter. The SEQ ID NO: 43 in co-pending claim 42 is 100% identical to the SEQ ID NO: 43 in instant claim 68. The co-pending claims do not teach an AAV Cap-Mac capsid protein. However, this was disclosed by Chuapoco et al.. Chuapoco et al. teach AAV.CAP-Mac, an engineered AAV9 variant that efficiently transduces multiple neuronal subtypes throughout cortical and subcortical brain regions of infant Old World primates after IV administration (p4, L86-88). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the rAAV comprising GM3S Ia Type 2 protein isoforms of the co-pending claims, and use AAV.CAP-Mac capsid protein as taught by Chuapoco et al.. The skilled artisan would have been motivated to use AAV.CAP-Mac capsid protein to efficiently transduce the rAAVs to multiple neuronal subtypes throughout cortical and subcortical brain regions. There would be a reasonable expectation of success of having AAV.CAP-Mac capsid protein since Chuapoco et al. teach the CAP-Mac selection and mutation site comparing to AAV9 (see figure 1). Regarding claim 60, co-pending claims 57 and 58 teach the transgene comprising a promoter operably linked to the nucleic acid sequence encoding the GM3 synthase Ia Type 2 protein isoform, wherein the promoter is a chicken beta-actin (CBA) promoter. Regarding claim 69, co-pending claims 61-62 teach the rAAV comprises a fourth region comprising one or more miRNA binding sites, rendering obvious to instant claim. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QINHUA GU whose telephone number is (703)756-1176. The examiner can normally be reached M-F: 9:00 - 5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher Babic can be reached at (571)272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Q.G./Examiner, Art Unit 1633 /FEREYDOUN G SAJJADI/Supervisory Patent Examiner, Art Unit 1699 Sequence Alignment SEQ ID NO: 8 in instant application v.s. SEQ ID NO: 8 in WO 2020/210570 (PCT/US2020/027585): PNG media_image1.png 232 775 media_image1.png Greyscale PNG media_image2.png 611 776 media_image2.png Greyscale SEQ ID NO: 1 in instant application v.s. SEQ ID NO: 1 in WO 2020/210570 (PCT/US2020/027585): PNG media_image3.png 240 796 media_image3.png Greyscale PNG media_image4.png 822 776 media_image4.png Greyscale PNG media_image5.png 757 757 media_image5.png Greyscale PNG media_image6.png 760 765 media_image6.png Greyscale PNG media_image7.png 757 748 media_image7.png Greyscale PNG media_image8.png 757 767 media_image8.png Greyscale PNG media_image9.png 753 736 media_image9.png Greyscale PNG media_image10.png 153 847 media_image10.png Greyscale
Read full office action

Prosecution Timeline

Oct 25, 2023
Application Filed
Apr 29, 2026
Non-Final Rejection mailed — §103, §DP
Jul 27, 2026
Response Filed
Oct 01, 2026
Non-Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773387
INJECTION FORMULATION COMPOSITION CONTAINING MESENCHYMAL STEM CELL-HYDROGEL AND METHOD FOR PREPARING, FREEZING AND DEFROSTING SAME
5y 1m to grant Granted Oct 27, 2026
Patent 12774452
METHOD FOR PREPARATION OF MESENCHYMAL STEM CELL FROM HUMAN PLURIPOTENT STEM CELL AND MESENCHYMAL STEM CELLS PREPARED THEREBY
4y 4m to grant Granted Oct 27, 2026
Patent 12760347
CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN
5y 1m to grant Granted Oct 13, 2026
Patent 12758653
LENTIVIRAL VECTORS IN HEMATOPOIETIC STEM CELLS TO TREAT X-LINKED CHRONIC GRANULOMATOUS DISEASE
4y 5m to grant Granted Oct 13, 2026
Patent 12753418
COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOPHILIA
3y 1m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+26.6%)
3y 9m (~9m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 86 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month